OP0240 A RANDOMIZED CONTROLLED TRIAL TO COMPARE THE EFFICACY OF TACROLIMUS WITH MYCOPHENOLATE MOFETIL IN PATIENTS WITH SYSTEMIC SCLEROSIS - INTERSTITIAL LUNG DISEASE (INSIST TRIAL)

医学 霉酚酸酯 他克莫司 间质性肺病 内科学 疾病 随机对照试验 移植 肺
作者
Jithin Mathew,Chirag Rajkumar Kopp,Shefali Sharma,Varun Dhir,Sahajal Dhooria,Anindita Sinha,Sanjay Jain
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:: 160.1-160 被引量:2
标识
DOI:10.1136/annrheumdis-2023-eular.3107
摘要

Background

Interstitial lung disease in systemic sclerosis(SSc-ILD) is heterogeneous with limited therapeutic options. Mycophenolate mofetil (MMF) is the most commonly used first line agent for SSc-ILD. Tacrolimus has shown promising efficacy in few small case series, and large cohorts of patients with non-SSC-ILD[1], but has never been evaluated in the setting of a clinical trial.

Objectives

To compare the safety and efficacy of Tacrolimus with MMF in patients with progressive SSc-ILD.

Methods

In this single center open labelled, prospective, two-arm parallel group, randomized controlled pilot study (INSIST) conducted between November 2021 to December 2022, patients with progressive ILD (FVC decline >10%) due to SSc, aged between 18-65 years, disease duration <10 years, without concomitant inflammatory myositis, with an FVC of 40-85%, and not having received active immunosuppression other than prednisolone <10mg/day in the last 6 months were randomized to receive either MMF (target dose 2gm/day) or tacrolimus (Max dose-0.075 mg/kg/day; target trough levels- 4-10ng/ml) for 24 weeks. The primary endpoint was the difference in change in FVC% at 24 weeks; secondary outcomes included absolute change in FVC, skin scores, 6-minute walk distance, Mahler's transitional dyspnea index, ACR-CRISS and revised CRISS responses and adverse outcomes. (Trial Reg: CTRI/2021/11/037864)

Results

25 out of 26 patients (13 in each group) completed 24 weeks follow up. Majority had Anti-Scl 70 positivity (73%) and limited skin disease. At 24 weeks, the mean change in FVC was 4.4% (10.6) and 6.92%(8.4) in the MMF and tacrolimus groups respectively (difference 2.52%, 95% CI (-10.3 to 5.18); p-0.500). All patients on tacrolimus and 85% of patients on MMF had stabilization (ΔFVC% -5% TO 5%) or improvement (ΔFVC%>10%) in lung function. Secondary outcomes were similar between two groups. Subgroup analyses stratified by ILD type, skin involvement at baseline, and early vs late SSc yielded similar results. The mean tacrolimus levels were 4.9 ng/ml(1.47) and the median dose needed to achieve these levels was 4mg/d. No serious adverse events were noted in either group; use of tacrolimus did not result in renal dysfunction or renal crises.

Conclusion

Tacrolimus resulted in comparable improvement to MMF across primary and secondary outcome measures at 24 weeks with a favorable safety profile in patients with SSc ILD. Larger studies with longer follow up are needed to investigate the role of calcineurin inhibitors in SSc.

Reference

[1]Ge Y, Zhou H et al. The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review. Clin Rheumatol. 2015 Dec 1;34(12):2097–103.

Acknowledgements:

NIL.

Disclosure of Interests

None Declared.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
只争朝夕的应助被科研通管家采纳,获得10
刚刚
刚刚
大个的应助被科研通管家采纳,获得10
刚刚
刚刚
无极微光的应助被科研通管家采纳,获得20
刚刚
njw完成签到,获得积分10
刚刚
传奇3的应助被科研通管家采纳,获得10
1秒前
汉堡包的应助被科研通管家采纳,获得10
1秒前
老刀完成签到,获得积分10
2秒前
2秒前
转山转水转出了自我完成签到,获得积分10
2秒前
每天都不想读文献完成签到,获得积分10
3秒前
66发布了新的文献求助10
5秒前
6秒前
6秒前
7Hz完成签到 ,获得积分10
6秒前
CCY完成签到,获得积分10
7秒前
安尔完成签到 ,获得积分10
7秒前
8秒前
在水一方的应助被无奈柚子采纳,获得10
8秒前
giA关注了科研通微信公众号
8秒前
xiao发布了新的文献求助10
10秒前
积极的裘发布了新的文献求助10
10秒前
jing完成签到 ,获得积分10
10秒前
陈凌雪发布了新的文献求助10
11秒前
11秒前
liyongfei完成签到,获得积分10
11秒前
7Hz关注了科研通微信公众号
12秒前
12秒前
李程辉完成签到 ,获得积分10
12秒前
irisyan完成签到 ,获得积分10
13秒前
King完成签到 ,获得积分10
13秒前
17秒前
xiahaijun发布了新的文献求助10
18秒前
18秒前
orixero的应助被66采纳,获得10
18秒前
18秒前
linaoctcn完成签到,获得积分10
19秒前
无聊的剑心完成签到,获得积分10
19秒前
jinxli完成签到 ,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190478
求助须知:如何正确求助?哪些是违规求助? 9577686
关于积分的说明 21853808
捐赠科研通 7789496
什么是DOI,文献DOI怎么找? 3436407
关于科研通互助平台的介绍 2560235
邀请新用户注册赠送积分活动 2483054